Trial Profile
A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PACE
- Sponsors ARIAD Pharmaceuticals; Takeda Pharma
- 15 Jun 2023 Results of post-hoc retrospective analysis of patients who achieved landmark cytogenetic and molecular responses at 3, 6, and 12 months, presented at the 28th Congress of the European Haematology Association.
- 13 Dec 2022 A propensity score analysis results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 14 Oct 2022 Results of pooled analysis assessing efficacy and safety outcomes from the Ponatinib Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and CML Evaluation (PACE) and Optimizing Ponatinib Treatment in CP-CML (OPTIC) trials for this patient population published in the American Journal of Hematology